Drugs Containing Excipient (Inactive Ingredient) HIGH DENSITY POLYETHYLENE

Branded drugs containing HIGH DENSITY POLYETHYLENE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	NICODERM	nicotine	0135-0194	HIGH DENSITY POLYETHYLENE
Kyowa Kirin Inc	SANCUSO	granisetron	42747-726	HIGH DENSITY POLYETHYLENE	1969-12-31

Generic drugs containing HIGH DENSITY POLYETHYLENE excipient

Company	Ingredient	NDC	Excipient
Haleon US Holdings LLC	nicotine	0135-0194	HIGH DENSITY POLYETHYLENE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	nystatin	0168-0007	HIGH DENSITY POLYETHYLENE
E Fougera & Co a division of Fougera Pharmaceuticals Inc	nystatin and triamcinolone acetonide	0168-0089	HIGH DENSITY POLYETHYLENE

High-Density Polyethylene Pharmaceutical Packaging Market: Dynamics, Financial Trajectory, and Competitive Outlook

Last updated: August 4, 2026

High-density polyethylene, or HDPE, is primarily a pharmaceutical packaging polymer rather than a pharmaceutical excipient. Its commercial outlook is stable, supported by demand for bottles, closures, canisters, and containers used for tablets, capsules, powders, and selected liquid products. Growth is likely to track pharmaceutical unit volumes at low- to mid-single-digit rates, while profitability will remain exposed to ethylene costs, polyethylene oversupply, energy prices, recycled-content regulation, and conversion costs.

The highest-value opportunities are in validated pharmaceutical grades, child-resistant and senior-friendly closure systems, desiccant-integrated bottles, specialty colorants, extractables-controlled formulations, and regional supply arrangements. Commodity HDPE resin has limited pricing power. Pharmaceutical packaging converters and qualified resin suppliers retain more defensible margins because switching requires regulatory documentation, stability testing, line validation, and customer approval.

Is high-density polyethylene a pharmaceutical excipient or a packaging material?

HDPE is generally a packaging material and is not a conventional active pharmaceutical ingredient excipient.

An excipient is an inactive ingredient intentionally incorporated into a drug formulation. HDPE is usually used outside the formulation as a container, bottle, closure, liner, or secondary packaging component. In pharmaceutical supply chains, it is more accurately classified as a plastic material of construction.

Common applications include:

Application	Typical HDPE role	Commercial assessment
Tablets and capsules	Bottles, wide-mouth containers, caps	Largest established use
Oral powders	Bottles and canisters	Strong fit where moisture protection is required
Liquid medicines	Bottles and dispensing containers	Requires compatibility and extractables testing
OTC products	Bottles and closures	High volume, greater price sensitivity
Nutraceuticals	Bottles and jars	Significant demand but less stringent qualification in some markets
Hospital and institutional packaging	Containers and closures	Driven by procurement and durability
Primary packaging components	Liners, caps, dispensing systems	Higher qualification burden
Injectable products	Limited use as direct primary container	Glass, cyclic olefin polymers, and polypropylene are more common

HDPE is valued for chemical resistance, impact strength, low density, moisture resistance, processability, and relatively low cost. Its principal technical limitation is weak oxygen and gas-barrier performance compared with glass, multilayer structures, and certain high-barrier plastics.

What regulatory standards apply to pharmaceutical HDPE?

Pharmaceutical HDPE packaging must comply with the requirements applicable to the drug product, manufacturing site, market, and packaging configuration. The resin itself does not receive an FDA drug approval.

In the United States, olefin polymers used in food-contact and related packaging applications are addressed under 21 C.F.R. § 177.1520. Pharmaceutical manufacturers also assess container suitability through stability, compatibility, extractables, leachables, light transmission, moisture transmission, and protection testing.

USP General Chapters <661.1> and <661.2> address plastic materials of construction and plastic packaging systems. The relevant evaluation depends on whether the component is the material itself or a complete packaging system.

In Europe, pharmaceutical packaging is assessed under EU GMP requirements, pharmacopoeial expectations, product-specific stability requirements, and applicable materials legislation. Food-contact compliance under Regulation (EU) No. 10/2011 may support a packaging qualification package but does not replace pharmaceutical suitability testing.

Key regulatory qualification tests

A pharmaceutical HDPE bottle or closure may require:

• Identification of the polymer and additives
• Biological reactivity assessment
• Extractables and leachables testing
• Water-vapor transmission testing
• Oxygen transmission testing where relevant
• Light-protection testing
• Closure-integrity testing
• Dimensional and mechanical testing
• Product-contact compatibility studies
• Accelerated and long-term stability studies
• Child-resistant or senior-friendly packaging testing
• Change-control documentation for resin, additives, tooling, and manufacturing sites

The regulatory burden creates switching costs. A drug company may be able to change from one qualified HDPE supplier to another, but the change can require comparability work, updated supplier qualification, stability data, and regulatory assessment.

What is driving demand for pharmaceutical HDPE?

Demand is tied to pharmaceutical packaging volume rather than to a separate therapeutic market. The main growth drivers are generic drugs, over-the-counter medicines, chronic-disease treatments, nutraceuticals, and expanding pharmaceutical production in emerging markets.

Oral solid dosage growth

HDPE remains a standard format for tablets and capsules. It is especially competitive where a bottle offers lower packaging cost, easier high-speed filling, and greater dosing flexibility than blister packaging.

Generic manufacturers are important buyers because HDPE bottles provide a low-cost, widely available format. The same cost pressure limits resin and converter pricing power. Customers often seek equivalent performance at lower total packaging cost.

Chronic therapies and adherence packaging

Chronic-care medicines support recurring demand for bottles and closures. Calendar packs, unit-dose formats, and adherence systems can increase the value of the packaging system, although some of these formats use polypropylene, PET, blister films, or multilayer structures instead of HDPE.

Emerging-market pharmaceutical manufacturing

Local pharmaceutical production in India, China, Southeast Asia, Latin America, and the Middle East supports demand for domestically converted packaging. Regional qualification and shorter supply chains are becoming more important as manufacturers seek to reduce freight exposure and avoid supply disruptions.

Sustainability requirements

HDPE is attractive in sustainability programs because it is widely recyclable and can incorporate post-consumer recycled resin in some applications. Pharmaceutical primary packaging has a higher barrier to recycled content than household packaging because of contamination, traceability, extractables, and consistency concerns.

Recycled HDPE is more commercially viable in secondary packaging, transport packaging, and selected non-contact components than in direct-contact pharmaceutical containers. The transition will depend on validated feedstock, mass-balance systems, regulatory acceptance, and customer-specific risk assessments.

How does pharmaceutical HDPE compare with PET, polypropylene, glass, and blister packaging?

HDPE competes on total cost, durability, moisture resistance, and supply availability. It does not dominate every packaging requirement.

Material	Main advantages	Main limitations	Competitive position
HDPE	Low cost, impact strength, chemical resistance, moisture protection	Limited oxygen barrier, lower premium image than glass	Strong for bottles and solid-dose products
PET	Clarity, stiffness, good appearance, broad availability	Different barrier profile, potential stress-cracking concerns	Strong for transparent liquid and OTC packaging
Polypropylene	Heat resistance, chemical resistance, closures and containers	Processing and barrier tradeoffs	Strong in caps, closures, and specialized containers
Glass	High barrier, low interaction, strong premium and injectable profile	Breakage, weight, transport cost	Strong for injectables and sensitive formulations
Blister films	Unit-dose format, adherence, tamper evidence	More complex material system and machinery	Strong for tablets and capsules requiring unit dosing
Cyclic olefin polymers	High purity and low extractables for sensitive products	High cost and limited use cases	Specialized biologic and injectable applications

HDPE is most defensible when the product requires a durable bottle, moderate moisture protection, low packaging cost, and established high-speed filling infrastructure.

What is the financial trajectory for pharmaceutical HDPE?

The financial trajectory is positive in volume but cyclical in margins. Pharmaceutical HDPE packaging should grow more steadily than commodity polyethylene because packaging demand is linked to healthcare consumption, but resin producers remain exposed to the broader petrochemical cycle.

Revenue drivers

Revenue growth comes from:

1. Pharmaceutical unit growth.
2. Higher use of specialty bottles, closures, and dispensing systems.
3. Conversion from glass or blister formats in selected products.
4. Regional pharmaceutical manufacturing expansion.
5. Premium grades with tighter extractables and consistency specifications.
6. New sustainability products and certified recycled-content offerings.

Margin drivers

Margins depend on:

• Ethylene and feedstock prices
• Natural gas and electricity costs
• Regional polyethylene capacity
• Freight and logistics costs
• Converter utilization
• Additive and colorant prices
• Tooling and validation costs
• Customer concentration
• Resin qualification status
• Recycled-content availability

Commodity HDPE prices typically move with polyethylene supply and demand. Pharmaceutical-grade packaging contracts can provide better visibility, but they do not eliminate feedstock exposure. Converters may use resin-indexed contracts, pass-through mechanisms, annual price reviews, or fixed-price agreements.

Financial outlook by value-chain position

Value-chain position	Revenue outlook	Margin outlook	Main risk
Ethylene producer	Linked to global petrochemical cycle	Volatile	Feedstock and capacity additions
Commodity HDPE resin producer	Volume growth with limited differentiation	Cyclical	Oversupply and price competition
Specialty pharmaceutical resin supplier	Moderate growth	Better than commodity grades	Qualification failure or limited scale
Packaging converter	Stable to moderate growth	Dependent on utilization and labor	Customer concentration and cost inflation
Closure and dispensing-system supplier	Higher value growth	Potentially stronger	Tooling, validation, and technical complexity
Contract packaging provider	Linked to drug demand	Service-oriented margins	Customer switching and compliance costs

The strongest financial position usually sits with suppliers that control both material formulation and converted packaging, or that have proprietary closure designs and regulatory support. Pure resin producers face more commoditization.

Which companies participate in the pharmaceutical HDPE supply chain?

The market is fragmented across resin producers, specialty compounders, bottle manufacturers, closure suppliers, and contract packagers.

Major polyethylene and petrochemical suppliers

Large global polyethylene producers include:

• ExxonMobil
• Dow
• LyondellBasell
• Chevron Phillips Chemical
• INEOS
• SABIC
• Borouge
• Braskem
• Reliance Industries
• Formosa Plastics

These companies generally sell polyethylene resin into broad industrial and packaging markets. Pharmaceutical customers often purchase through approved distributors or packaging converters rather than directly from the resin producer.

Pharmaceutical packaging manufacturers

Important packaging suppliers include:

• Gerresheimer
• Berry Global
• AptarGroup
• West Pharmaceutical Services
• Silgan Holdings
• Amcor
• CCL Industries
• Comar
• Drug Plastics
• VisiPak
• DWK Life Sciences

The relevant supplier set varies by format. HDPE bottles, child-resistant closures, desiccant systems, dispensing closures, and clinical packaging have different competitive structures.

The market has no single global company controlling pharmaceutical HDPE. Qualification status, regional manufacturing, mold availability, regulatory support, and customer relationships are often more important than resin capacity alone.

What manufacturing and intellectual-property barriers protect pharmaceutical HDPE suppliers?

The base HDPE polymer is mature and widely available. Basic composition patents generally do not create a durable barrier for pharmaceutical packaging buyers.

The more relevant barriers are operational and qualification-based:

• Narrow molecular-weight and density specifications
• Low extractables and leachables profiles
• Controlled additive packages
• Color and opacity consistency
• Clean manufacturing environments
• Validated extrusion blow-molding processes
• Container-closure integrity
• Child-resistant closure designs
• Desiccant integration
• Tamper-evident features
• Tooling ownership and production capacity
• Regulatory documentation and change-control systems
• Customer-specific stability data

Packaging companies may protect closure mechanisms, dispensing systems, bottle geometry, barrier structures, and manufacturing processes through patents. These rights are usually more relevant to differentiated packaging systems than to HDPE resin itself.

Geographic protection is also operational. A supplier may have global patents but only a limited number of qualified plants. A plant change can trigger customer validation and regulatory review, creating practical regional barriers.

What are the main risks to pharmaceutical HDPE demand?

Substitution by blister packaging

Blister packaging can improve unit-dose control, tamper evidence, and adherence. It can reduce bottle demand for tablets and capsules, particularly in regulated markets and hospital settings.

Substitution by PET

PET may replace HDPE when transparency, stiffness, shelf appearance, or specific liquid-product requirements are more important than HDPE's moisture-resistance profile.

Sustainability regulation

Extended producer responsibility laws, recycled-content mandates, packaging taxes, and corporate plastic-reduction targets can increase compliance costs. They may also create demand for recyclable mono-material packaging and certified recycled HDPE.

Resin oversupply

New polyethylene capacity, particularly in North America and the Middle East, can pressure resin prices and producer margins. Oversupply benefits packaging buyers but can reduce investment incentives for specialty-grade development.

Qualification and change-control risk

A resin reformulation, additive change, plant transfer, or supplier acquisition can create regulatory work for pharmaceutical customers. Suppliers that fail to maintain consistent documentation risk losing approved status.

Drug-product compatibility

HDPE is not universally suitable. Sorption, permeation, chemical interaction, light exposure, and moisture transfer can limit its use for sensitive formulations. These issues support alternative materials and multilayer packaging.

What is the Orange Book, Paragraph IV, and biosimilar status for pharmaceutical HDPE?

The Orange Book and Paragraph IV litigation are not applicable to HDPE as a packaging polymer.

HDPE is not an FDA-approved drug, does not receive new chemical entity exclusivity, and does not have an Orange Book listing. It cannot be challenged through an Abbreviated New Drug Application Paragraph IV certification in the same way as an innovator drug patent.

Biosimilar risk is also not applicable. Biosimilar approval concerns biologic medicines, whereas HDPE is a packaging material. The relevant legal issues are packaging patents, supply contracts, product liability, regulatory compliance, and qualification disputes.

What licensing deals and commercial agreements affect pharmaceutical HDPE?

Public licensing disclosures are limited because pharmaceutical HDPE is commonly purchased under private supply, distribution, contract manufacturing, and packaging agreements.

The most important commercial arrangements typically include:

• Resin supply agreements
• Approved-vendor agreements
• Toll-compounding contracts
• Packaging conversion agreements
• Tooling and mold-ownership contracts
• Contract packaging agreements
• Recycled-content certification arrangements
• Technology licenses for closure and dispensing systems
• Regional distribution agreements

Pricing can be indexed to polyethylene benchmarks or negotiated on a fixed basis. The commercial value of a supplier relationship increases when the supplier has completed product-specific qualification and owns validated tooling.

What litigation affects pharmaceutical HDPE?

Litigation risk is usually lower than in branded pharmaceuticals but can arise from:

• Patent disputes involving child-resistant closures
• Trade-secret claims concerning mold design or processing
• Product-liability claims involving container failure
• Container-closure integrity failures
• Contamination or extractables events
• Regulatory noncompliance
• Contract disputes over resin substitutions
• Intellectual-property disputes involving dispensing systems

The most material business risk is often a recall or supply interruption rather than a patent injunction. A packaging failure can affect multiple drug products using the same bottle or closure platform.

What generic-entry risks exist for pharmaceutical HDPE suppliers?

Generic drug launches can increase HDPE demand because generic manufacturers often use cost-efficient bottles. The risk is that generic competition compresses packaging budgets and encourages resin substitution.

The commercial effects are mixed:

• Higher generic unit volumes support packaging volume.
• Lower drug prices increase procurement pressure.
• Customers may switch converters or resin grades after qualification.
• Standardized bottle formats limit supplier differentiation.
• Contract manufacturers can shift volume between regions.
• Specialty closures and validated systems retain better pricing power.

HDPE suppliers are therefore exposed to pharmaceutical volume growth but not insulated from generic procurement discipline.

What is the competitive outlook for pharmaceutical HDPE?

The outlook is moderate growth with selective premiumization.

Commodity HDPE will remain highly competitive. Specialty pharmaceutical packaging will have better economics where it combines regulatory documentation, low extractables, reliable supply, closure functionality, and sustainability credentials.

The most attractive segments are:

• Validated oral-solid-dose bottles
• Child-resistant closures
• Desiccant bottle systems
• High-consistency pharmaceutical grades
• Low-extractables packaging
• Regional supply for emerging-market manufacturers
• Recycled-content solutions with documented compliance
• Integrated resin-to-container supply models

The least attractive segments are undifferentiated commodity bottles exposed to annual price tenders and multiple qualified suppliers.

Key Takeaways

• HDPE is mainly a pharmaceutical packaging material, not a conventional formulation excipient.
• Demand is tied to oral solid doses, OTC products, generics, nutraceuticals, and regional pharmaceutical manufacturing.
• Volume growth should be steadier than commodity polyethylene, but resin and converter margins remain cyclical.
• Feedstock costs, polyethylene oversupply, energy prices, freight, and recycled-content rules are the main financial variables.
• The strongest barriers are qualification, validated manufacturing, closure technology, documentation, and supply reliability rather than basic HDPE chemistry patents.
• Orange Book listings, Paragraph IV challenges, biosimilar litigation, and drug exclusivity do not apply to HDPE itself.
• Blister packaging, PET, polypropylene, glass, and multilayer systems are the main substitutes.
• Specialty grades, closures, desiccant systems, and integrated packaging services offer better margin potential than commodity HDPE bottles.
• Geographic coverage depends on qualified plants, tooling, regulatory support, and supply continuity.
• The sector's financial trajectory is favorable for specialized converters and qualified suppliers, but less attractive for undifferentiated resin producers.

FAQs About Pharmaceutical HDPE

Can HDPE be used for liquid pharmaceutical products?

Yes. HDPE is used for selected oral liquids, suspensions, powders, and concentrates, subject to compatibility, permeability, extractables, leachables, and stability testing.

Is pharmaceutical-grade HDPE different from ordinary HDPE?

It can be. Pharmaceutical-grade material may have tighter controls on molecular properties, additives, color, cleanliness, traceability, and change notification. The exact requirements are customer- and product-specific.

Does HDPE protect medicines from moisture?

HDPE provides useful moisture resistance, especially compared with some other plastics, but performance depends on wall thickness, closure design, liner, desiccant, and container geometry.

Is recycled HDPE allowed in pharmaceutical bottles?

Potentially, but use in direct-contact packaging requires regulatory justification, consistent feedstock, contamination controls, extractables assessment, and customer approval. Adoption is generally easier in secondary and non-contact packaging.

Which packaging material is better than HDPE for oxygen-sensitive medicines?

Glass, multilayer structures, specialized barrier plastics, and selected cyclic olefin polymers may provide better oxygen protection. The appropriate choice depends on formulation sensitivity, dosage form, stability profile, and manufacturing process.

References

1. European Commission. (2011). Commission Regulation (EU) No. 10/2011 on plastic materials and articles intended to come into contact with food. Official Journal of the European Union.

2. European Commission. (2015). EudraLex, Volume 4: EU guidelines for good manufacturing practice for medicinal products for human and veterinary use, Annex 1 and Annex 15. European Commission.

3. U.S. Food and Drug Administration. (2024). 21 C.F.R. § 177.1520: Olefin polymers. Code of Federal Regulations.

4. United States Pharmacopeia. (2024). General Chapter <661.1>: Plastic materials of construction. United States Pharmacopeial Convention.

5. United States Pharmacopeia. (2024). General Chapter <661.2>: Plastic packaging systems for pharmaceutical use. United States Pharmacopeial Convention.

6. Dow Inc. (2025). 2024 annual report. Dow Inc.

7. Exxon Mobil Corporation. (2025). 2024 annual report. Exxon Mobil Corporation.

8. LyondellBasell Industries N.V. (2025). 2024 annual report. LyondellBasell Industries N.V.

9. European Plastics Converters. (2024). Trends and challenges in European plastics conversion. EuPC.